Debiostar

Available for license.

(Currently under development)

An innovative solution for sustained drug delivery

DebioSTAR^TM is an innovative implantable drug delivery technology for the sustained delivery of pharmaceutical compounds.

Fig.1
The pores diameters are 3 orders of magnitude smaller than a typical human cell
(comparison between red blood cells and atomic force microscope picture of the membrane)

Fig.2

By use of a perfectly controlled nanoporous membrane, the drug can be delivered from an implantable system over several weeks to several months. The delivery profile can be tailored to specific pharmacokinetic requirements by modification of the size as well as the thickness of the membrane. Additional surface chemistry can be added to the membrane in order to delay the delivery over a prolonged period of time.

Fig.3
The pores are running parallel through the layer while the length can be less than 50nm and more than 150µm

The membrane is fully biocompatible and can be used for a long term, allowing its use in "refillable" as well as "single use" implantable systems.

Fig.4
1)Pore size controlled drug delivery
2)Coating for local drug delivery

The DebioSTAR^TM technology is intended to be used for local drug delivery as well as systemic drug delivery (subcutaneous, intra-peritoneal or intra-muscular).

The unique characteristics of the nanoporous membrane are based on a novel and patented manufacturing process. Such membrane can incorporate highly controlled pores of as small as one nanometre size, up to 250 nanometres. All pores are almost identical and highly controlled in size and dimensions.

The number of pores can be as high as one billion pores/cm². The thickness of the membrane can be between 50 nanometres and several hundreds of micrometres.

Testing of the membrane with different drugs has already shown a very linear release from several days to several months, in vitro.

Fig.5
Oligopeptide - Somatostatin molecule

Fig.6
Increasing the pore diameter leads to an increase in the delivery rate
Test substance: Oligopeptide - Somatostatin

Fig.7
Changing the surface properties leads to a drastical change in the rate.
example with an Oligopeptide - Somatostatin molecule

Anticancer drug results in DebioStar (30mg)

Fig.8
Long term in-vitro results with 30mg of an Anticancer
drug substance in powder form over 150 days.

DebioSTAR^TM can be used as a passive device as well as an active pressurized system (e.g. osmotic pressure).

Fig.9
Example of a refillable implantable cartridge for chronic desease treatment.

The intent of Debiotech is to propose this innovative technology to pharmaceutical companies to offer a new range of therapeutic options, thereby increasing the efficacy and/or convenience of continuous therapy regimens. The first candidates are peptides, hormones, anti-cancer drugs, NSAI and CNS drugs.